ALK and neuroblastoma: In about 10% of sporadic tumors, ALK amplification is seen, which is often co-amplified with MYCN. Determining the underlying drivers of neuroblastoma tumorigenesis provides important information about prognosis (MYCN amplification is associated with aggressive clinical behavior) and precision medicine (ALK mutations).